CEACAM5 and neoplasm: CEA-targeted CAR T-cells are also under investigation in PDAC and biliary cancers in early-phase trials (e.g., NCT02744287), utilizing both systemic and hepatic artery infusion to localize therapy while minimizing off-tumor effects [132].